This time, 95 percent of the effectiveness is matched in the Russian-made corona vaccine 'Sputnik-5'. This information was obtained by analyzing the results of the second trial of the vaccine. Earlier, analyzing the data of the first phase, it was found that the effectiveness of the vaccine was 91.4%.
This was confirmed in a joint statement issued on Tuesday (November 24) by the Gamalea Research Center, the manufacturer of the Sputnik-5 vaccine, the Russia Direct Investment Fund (RDIF) and the Russian Ministry of Health.
The vaccine made in Russia can be stored at a temperature of 2 to 6 degrees Celsius. The manufacturer claims that the Sputnik-5 will be available in the international market at a price of less than10 dollar per dose, at around Tk. 8,000 in Bangladesh currency.
However, the Russian government has announced that the vaccine will be provided free of charge to its own people. Alexander Gintzberg, director of the Gamalea Research Center, said in a statement that the second analysis data was collected a week after the second dose of the vaccine was given. This means that their bodies have partially responded to both doses. He also said that the effectiveness of the vaccine may increase in the future.
The coronavirus vaccine, developed by Oxford University and AstraZeneca in the United Kingdom, has shown to be up to 90 percent effective when given half a dose a month after a full dose. Earlier last week, Pfizer-BioNtech and Moderna announced the third phase test of their vaccine. Both companies claimed that their vaccines are 95 percent effective in protecting against corona. Pfizer has already applied to the US Food and Drug Administration (FDA) for approval of the emergency use of the vaccine.